
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT
- About
Pasithea Therapeutics Corp (KTTA)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: KTTA (1-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $2
1 Year Target Price $2
1 | Strong Buy |
0 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -51.68% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 5.65M USD | Price to earnings Ratio - | 1Y Target Price 2 |
Price to earnings Ratio - | 1Y Target Price 2 | ||
Volume (30-day avg) 1 | Beta 0.34 | 52 Weeks Range 0.70 - 7.50 | Updated Date 06/30/2025 |
52 Weeks Range 0.70 - 7.50 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -10.6 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -46.84% | Return on Equity (TTM) -82.81% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -6326684 | Price to Sales(TTM) 42.15 |
Enterprise Value -6326684 | Price to Sales(TTM) 42.15 | ||
Enterprise Value to Revenue 277.44 | Enterprise Value to EBITDA 2.9 | Shares Outstanding 7443580 | Shares Floating 6931236 |
Shares Outstanding 7443580 | Shares Floating 6931236 | ||
Percent Insiders 3.27 | Percent Institutions 13.22 |
Analyst Ratings
Rating 1 | Target Price 2 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Pasithea Therapeutics Corp
Company Overview
History and Background
Pasithea Therapeutics Corp. is a biotechnology company focused on the discovery, research and development of new and effective treatments for central nervous system (CNS) disorders. The company was founded in 2019.
Core Business Areas
- CNS Therapeutics Development: Focuses on developing novel treatments for psychiatric and neurological disorders, utilizing psychedelic-based therapies and other innovative approaches. Currently focusing on NET-100A, a PAS agonist.
Leadership and Structure
The leadership team consists of experienced professionals in the pharmaceutical and biotechnology industries. The organizational structure includes research and development, clinical operations, and business development functions.
Top Products and Market Share
Key Offerings
- NET-100A: A PAS agonist being developed for the treatment of Multiple Sclerosis and potentially other neurological disorders. Currently in preclinical development. Competitors include large pharmaceutical companies with established MS drugs (e.g., Novartis, Biogen).
Market Dynamics
Industry Overview
The CNS therapeutics market is large and growing, driven by the increasing prevalence of mental health disorders and neurological diseases. There's a rising interest in novel approaches, including psychedelic-assisted therapies, although still in early stages.
Positioning
Pasithea is a relatively small player in the CNS therapeutics market, focusing on innovative treatments. Its competitive advantage lies in its focus on unique treatment mechanisms.
Total Addressable Market (TAM)
The total addressable market for CNS therapeutics is estimated in the hundreds of billions of dollars. Pasithea is targeting niche segments within this large market, such as specific neurological disorders, with the NET-100A PAS agonist.
Upturn SWOT Analysis
Strengths
- Novel treatment approach (PAS agonism)
- Experienced management team
- Focus on underserved CNS markets
Weaknesses
- Limited financial resources
- Early stage of development (preclinical)
- High regulatory risk
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new CNS indications
- Positive clinical trial results
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Failure of clinical trials
- Limited Funding
Competitors and Market Share
Key Competitors
- BIIB
- NVS
Competitive Landscape
Pasithea faces intense competition from established pharmaceutical companies with larger R&D budgets and existing market presence. Its success depends on demonstrating superior efficacy and safety in clinical trials.
Growth Trajectory and Initiatives
Historical Growth: N/A, early stage company.
Future Projections: Future growth depends on the successful development and commercialization of its product candidates, especially NET-100A. Analyst projections are speculative at this point.
Recent Initiatives: Focusing on preclinical and clinical trial design and development for NET-100A.
Summary
Pasithea Therapeutics is a very early stage, high-risk, high-reward biotechnology company focused on innovative CNS therapies. Their success hinges on their ability to successfully progress NET-100A through clinical trials and secure funding. They should be aware of funding risks and intense competition from larger pharmaceuticals.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website, SEC filings, publicly available information, Analyst reports.
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. The information provided is based on available data and is subject to change. Investing in early-stage biotechnology companies involves significant risks.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Pasithea Therapeutics Corp
Exchange NASDAQ | Headquaters Miami Beach, FL, United States | ||
IPO Launch date 2021-09-15 | CEO & Director Dr. Tiago Reis Marques M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 4 | Website https://www.pasithea.com |
Full time employees 4 | Website https://www.pasithea.com |
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumors; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.